The cGAS-STING pathway is a major cellular system for detecting misplaced DNA and initiating innate immune responses. It can be activated by microbial DNA, mitochondrial damage, genome instability, or defective nucleic-acid clearance. Once activated, cGAS produces cGAMP, which binds to STING and triggers its intracellular trafficking and downstream inflammatory signaling.
A new review in Medicine Plus presents cGAS-STING as a spatially organized and highly context-dependent signaling network rather than a simple linear pathway. The authors summarize how STING trafficking, metabolic and stress-response pathways, and feedback from mitochondria together shape the strength, duration, and outcome of signaling.
This framework helps explain why cGAS-STING can have opposite effects in different diseases. Acute and controlled activation generally supports antimicrobial defense and antitumor immune surveillance, whereas persistent or dysregulated signaling can contribute to autoimmunity, fibrosis, aging-related inflammation, metabolic and cardiovascular injury, and tumor progression. In cancer, for example, short-term STING activation can enhance immune responses, while chronic signaling may promote immune evasion, metastasis, and treatment resistance. Similar context-dependent effects are observed in systemic lupus erythematosus.
The review also highlights recent therapeutic advances, including orally active non-nucleotide modulators, manganese-based immunotherapy, tissue-targeted delivery systems, central nervous system-accessible inhibitors, and targeted degradation of cGAS or STING.
The authors emphasize that future therapies should move beyond simply activating or inhibiting the pathway. Effective treatment may require precise control of where, how strongly, and for how long cGAS-STING is modulated, together with biomarker-based patient selection and disease-specific treatment strategies.
Medicine Plus
Literature review